Lexicon Pharmaceuticals, Inc. — Q1 2013 Form 10-Q
Business context and reporting period
Lexicon is a biopharmaceutical company focused on discovering and developing treatments for human disease, with programs at various clinical and preclinical stages. The unaudited results cover the three months ended March 31, 2013; comparisons are with Q1 2012 unless noted. The company reports that it has a history of losses and expects to continue incurring significant research and development costs.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 / prior date |
|---|---|---|
| Revenue | $0.36 million | $0.30 million |
| Research and development expense | $20.3 million | $23.0 million |
| General and administrative expense | $4.3 million | $4.6 million |
| Operating loss | $25.6 million | $29.4 million |
| Net loss | $26.0 million | $29.9 million |
| Net loss per share | $0.05 | $0.06 |
| Net cash used in operating activities | $24.3 million | $27.0 million |
| Cash, cash equivalents and short-term investments | $197.2 million | $223.2 million at Dec. 31, 2012 |
| Total debt, including current portion | $23.1 million | $23.5 million at Dec. 31, 2012 |
Operating expenses totaled $25.9 million, against $0.36 million in revenue; the filing does not present a gross margin measure. Cash and cash equivalents were $34.2 million and short-term investments were $162.9 million at quarter-end. Investing activities provided $29.1 million, mainly from net investment maturities; financing activities used $1.0 million, primarily for debt repayment and share repurchases. The mortgage bears fixed interest at 8.23%; its principal balance was approximately $23.1 million.
Material changes versus Q1 2012
- Revenue increased 20%: collaborative research revenue rose 87% to $0.3 million, primarily from the Taconic Farms alliance, while subscription and license fees fell 49% to $0.1 million.
- R&D expense decreased 12%, mainly reflecting lower personnel, external development, facilities and laboratory supply costs. G&A expense decreased 5%.
- Net loss narrowed by approximately $3.9 million. The Symphony Icon purchase liability fair-value expense also declined, to $1.3 million from $2.1 million.
- Cash, cash equivalents and investments declined by $26.0 million from year-end. Operating cash use was partly offset by investment maturities.
Outlook, risks and contingencies
- Management believes unrestricted cash and investments, together with expected cash and revenues, will fund operations for at least the next 12 months. Future capital needs depend on R&D spending and the timing and success of collaborations and licenses; additional financing may be needed and may not be available on acceptable terms.
- A $21.4 million mortgage balloon payment is due in April 2014. Management identifies additional financing, continued losses, drug-development and regulatory uncertainty, dependence on collaborators, and commercialization and intellectual-property risks.
- Under the Symphony Icon arrangement, Lexicon may owe up to $45 million in contingent payments, generally tied to qualifying licensing proceeds or specified U.S. regulatory approval. The recorded Symphony Icon purchase consideration liability was $31.2 million at March 31, 2013 and is based on Level 3 valuation inputs.
- Lexicon could be required to repay up to approximately $14.2 million under its Texas Enterprise Fund job-creation obligations if it fails to meet the requirements, before applicable credits. A New Jersey lease guarantee has maximum potential future payments of $5.3 million; $0.4 million of restricted investments collateralized a letter of credit.
- The company reported ordinary-course legal proceedings that it believes will not have a material adverse effect. No specific new guidance or revenue forecast is provided.
Important facts for investors to verify
- Whether the stated minimum 12-month liquidity runway adequately accounts for the April 2014 mortgage balloon and ongoing operating cash burn.
- Progress and potential financing, licensing, or contingent-payment implications of clinical programs, including the LG103 programs and Symphony Icon obligations.
- Achievement of Texas job-creation commitments and any resulting repayment exposure.
- Dependence on collaborations and licenses for revenue, and the clinical, regulatory, financing, and commercialization risks described in the filing.